PER-089-08已完成未知
A MULTICENTER, DOUBLE BLIND, RANDOMIZED, CONTROLLED WITH ACTIVE COMPARATOR STUDY TO EVALUATE THE SAFETY AND ANTIRETROVIRAL ACTIVITY OF MK-0518 AGAINST KALETRA ™ IN PATIENTS INFECTED WITH HIV TRANSFERRED FROM A STABLE REGIME BASED ON KALETRA ™ - STUDY B
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 0 人开始时间: 2008年11月13日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •The patient is a man or woman of at least 18 years of age on the day of signing the informed consent.
- •The patient is HIV positive according to the determination of the enzyme-linked immunosorbent assay (ELISA) or the HIV RNA of the documented medical history.
- •The patient has a POR of the RNA of! Documented HIV <50 copies / mL (or bDNA <75 copies / mL) for a minimum of 3 months before entering the study while receiving a regimen based on KALETRA ™ (dosed as 400 mg lopinavir / 100 mg ritonavir), consisting of KALETRA in combination with at least 2 nRTI (reverse transcriptase inhibitors) without a change in antiretroviral therapy and without any documentation of HIV RNA> 50 copies / mL during this time.
- •The patient has no history of coronary artery disease.
- •The patient has the following laboratory values within 35 days prior to the treatment phase of this study: Alkaline Phosphatase <5.0 x normal upper limit, AST (SGOT) and ALT (SGPT) <5.0 x normal upper limit. Patients with a chronic coinfection of Hepatitis B and / or C can be enrolled as long as patients are stable and meet all eligibility criteria.
- •The patient does not present clinical evidence of active lung disease; A chest x-ray may be obtained if deemed necessary by the investigator.
- •The patient is potentially fertile and agrees to use an acceptable method of contraception throughout the study. An acceptable method of contraception is defined as intrauterine device (IUD), diaphragm with spermicide, condoms or abstinence. Oral contraceptives are not recommended in this study because contraceptive steroid concentrations may be altered when KALETRA is coadministered with oral contraceptives or contraceptive patches or the patient who is not potentially fertile is not sexually active, whose ( s) current partner (s) are not / are potentially fertile, or whose sexual activity is exclusively homosexual is eligible without the use of contraceptive methods.
- •The patient agrees not to take the concomitant prohibited drugs as described in Section 3.2.1 of the protocol.
排除标准
- •The patient is receiving a regimen based on KALETRA ™ that includes Stavudine (d4T) as a component of background antiretroviral therapy.
- •The patient is receiving a regimen based on KALETRA ™ that includes a second protease inhibitor in addition to KALETRA.
- •The patient is currently receiving, or has received in the last twelve weeks, agents known to have an effect on lipid levels (eg, fish oils, lipidol, bile acid sequestrants, HMG-CoA reductase inhibitors) [such as simvastatin, atorvastatin, rosuvastatin], ezetimibe, ezetimibe / simvastatin, fibrates, niacin, plant sterols, and / or red yeast).
- •The patient has a medical history that includes diabetes mellitus.
- •The patient has a current history or evidence of any condition, therapy, laboratory abnormality or other circumstance that could confuse the results of the study, or interfere with the patient´s participation throughout the study, so that the patient does not feel the best interest to participate.
- •The patient has a history of alcoholism or abuse of other substances that, in the opinion of the investigator, could interfere with the patient´s compliance or safety.
- •The patient is currently participating or has participated in a study with a compound or device under investigation within 30 days of signing the informed consent.
- •The patient has ever used any experimental inhibitor of HIV integrase.
- •The patient has used a systemic immunosuppressive therapy (eg, 20 mg or more of prednisone or equivalent per day) within one month before treatment in this study. Short courses of corticosteroids will be allowed (for example, for the exacerbation of asthma).
- •The patient requires hemodialysis.
- •The patient has significant hypersensitivity or another contraindication to any of the components of the study drugs.
- •The patient has chronic hepatitis, with evidence of unstable liver function. This includes patients who, in the opinion of the investigator, present evidence of synthetic liver dysfunction, such as hypoalbuminemia or prolonged PT and PTT.
- •The patient is pregnant or breastfeeding, or expects to conceive (within the duration of the study). The patient is estimating to donate ovules (within the duration of the study). The patient is estimating to donate sperm (within the duration of the study).
研究者
相似试验
已完成
不适用
A MULTICENTER, DOUBLE BLIND, RANDOMIZED, CONTROLLED STUDY WITH ACTIVE COMPARATOR TO EVALUATE THE SECURITY AND ANTIRETROVIRAL ACTIVITY OF MK-0518 COMPARED WITH EFAVIRENZ IN PATIENTS INFECTED WITH HIV NOT SUBJECT TO TREATMENT, EACH IN COMBINATION WITH TRUVADA ™ - EXTENSION STUDYPER-066-08MERCK SHARP & DOHME PERU S.R.L.,43
进行中（未招募）
1 期
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIBocally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.MedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2007-001915-52-SKPfizer Inc. - 235 East 42nd Street - New York - 10017956
进行中（未招募）
1 期
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIBEUCTR2007-001915-52-BEPfizer Inc. - 235 East 42nd Street - New York - 10017956
进行中（未招募）
不适用
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB - not applicableEUCTR2007-001915-52-NLPfizer Inc. - 235 East 42nd Street - New York - 10017956
进行中（未招募）
1 期
A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIBocally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.MedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2007-001915-52-FRPfizer Inc. - 235 East 42nd Street - New York - 10017956